Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy

Journal of Lipid Research

Volumn 51, Issue 10, 2010, Pages 3055-3061

  Nicholls, Stephen J ^a   Tang, W H Wilson ^a,b   Scoffone, Heather ^b   Brennan, Danielle M ^b   Hartiala, Jaana ^c   Allayee, Hooman ^c   Hazen, Stanley L ^a,b  

^a Heart and Vascular Institute ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Coronary angiography; Risk factor

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DEATH; FEMALE; GENETIC POLYMORPHISM; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; STROKE;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEIN(A); MALE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 77956849517     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M008961     Document Type: Article

References (33)

1. Stamler, J., D. Wentworth, and J. D. Neaton. 1986. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256: 2823-2828.
2. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
3. Anuurad, E., M. B. Boffa, M. L. Koschinsky, and L. Berglund. 2006. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin. Lab. Med. 26: 751-772. (Pubitemid 44716507)
4. Berglund, L., and R. Ramakrishnan. 2004. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol. 24: 2219-2226. (Pubitemid 39658021)
5. Boffa, M. B., S. M. Marcovina, and M. L. Koschinsky. 2004. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin. Biochem. 37: 333-343.
6. Koschinsky, M. L. 2005. Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. Curr. Atheroscler. Rep. 7: 389-395.
7. Bennet, A., E. Di Angelantonio, S. Erqou, G. Eiriksdottir, G. Sigurdsson, M. Woodward, A. Rumley, G. D. Lowe, J. Danesh, and V. Gudnason. 2008. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch. Intern. Med. 168: 598-608.
8. Craig, W. Y., L. M. Neveux, G. E. Palomaki, M. M. Cleveland, and J. E. Haddow. 1998. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin. Chem. 44: 2301-2306.
9. Danesh, J., R. Collins, and R. Peto. 2000. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 102: 1082-1085.
10. Rifai, N., J. Ma, F. M. Sacks, P. M. Ridker, W. J. Hernandez, M. J. Stampfer, and S. M. Marcovina. 2004. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians' Health Study. Clin. Chem. 50: 1364-1371.
11. Suk Danik, J., N. Rifai, J. E. Buring, and P. M. Ridker. 2006. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 296: 1363-1370.
12. Suk Danik, J., N. Rifai, J. E. Buring, and P. M. Ridker. 2008. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J. Am. Coll. Cardiol. 52: 124-131.
13. Bolibar, I., S. G. Thompson, A. von Eckardstein, M. Sandkamp, and G. Assmann. 1995. Dose-response relationships of serum lipid measurements with the extent of coronary stenosis. Strong, independent, and comprehensive. ECAT Angina Pectoris Study Group. Arterioscler. Thromb. Vasc. Biol. 15: 1035-1042.
14. Bolibar, I., A. von Eckardstein, G. Assmann, and S. Thompson. 2000. Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb. Haemost. 84: 955-960.
15. Berg, K., G. Dahlen, B. Christophersen, T. Cook, J. Kjekshus, and T. Pedersen. 1997. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin. Genet. 52: 254-261. (Pubitemid 28068613)
16. Schaefer, E. J., S. Lamon-Fava, J. L. Jenner, J. R. McNamara, J. M. Ordovas, C. E. Davis, J. M. Abolafia, K. Lippel, and R. I. Levy. 1994. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 271: 999-1003.
17. Cremer, P., D. Nagel, B. Labrot, H. Mann, R. Muche, H. Elster, and D. Seidel. 1994. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur. J. Clin. Invest. 24: 444-453.
18. Seed, M., F. Hoppichler, D. Reaveley, S. McCarthy, G. R. Thompson, E. Boerwinkle, and G. Utermann. 1990. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N. Engl. J. Med. 322: 1494-1499.
19. Chasman, D. I., D. Shiffman, R. Y. Zee, J. Z. Louie, M. M. Luke, C. M. Rowland, J. J. Catanese, J. E. Buring, J. J. Devlin, and P. M. Ridker. 2009. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 203: 371-376.
20. Kamstrup, P. R., A. Tybjaerg-Hansen, R. Steffensen, and B. G. Nordestgaard. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 301: 2331-2339.
21. Tregouet, D. A., I. R. Konig, J. Erdmann, A. Munteanu, P. S. Braund, A. S. Hall, A. Grosshennig, P. Linsel-Nitschke, C. Perret, M. DeSuremain, et al. 2009. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet. 41: 283-285.
22. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, et al. 2009. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518-2528.
23. Erqou, S., A. Thompson, E. Di Angelantonio, D. Saleheen, S. Kaptoge, S. Marcovina, and J. Danesh. 2010. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J. Am. Coll. Cardiol. 55: 2160-2167.
24. Tang, W. H., Y. Wu, S. J. Nicholls, D. M. Brennan, M. Pepoy, S. Mann, A. Pratt, F. Van Lente, and S. L. Hazen. 2010. Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation. Arterioscler. Thromb. Vasc. Biol. 30: 634-640.
25. Ober, C., A. S. Nord, E. E. Thompson, L. Pan, Z. Tan, D. Cusanovich, Y. Sun, R. Nicolae, C. Edelstein, D. H. Schneider, et al. 2009. Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J. Lipid Res. 50: 798-806.
26. Luke, M. M., J. P. Kane, D. M. Liu, C. M. Rowland, D. Shiffman, J. Cassano, J. J. Catanese, C. R. Pullinger, D. U. Leong, A. R. Arellano, et al. 2007. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 27: 2030-2036.
27. Dahlen, G., C. Ericson, C. Furberg, L. Lundkvist, and K. Svardsudd. 1972. Studies on an extra pre-beta lipoprotein fraction. Acta Med. Scand. Suppl. 531: 1-29.
28. Ladenson, P. W., J. D. Kristensen, E. C. Ridgway, A. G. Olsson, B. Carlsson, I. Klein, J. D. Baxter, and B. Angelin. 2010. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N. Engl. J. Med. 362: 906-916.
29. Armstrong, V. W., P. Cremer, E. Eberle, A. Manke, F. Schulze, H. Wieland, H. Kreuzer, and D. Seidel. 1986. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 62: 249-257.
30. Cantin, B., F. Gagnon, S. Moorjani, J. P. Despres, B. Lamarche, P. J. Lupien, and G. R. Dagenais. 1998. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J. Am. Coll. Cardiol. 31: 519-525.
31. Maher, V. M., B. G. Brown, S. M. Marcovina, L. A. Hillger, X. Q. Zhao, and J. J. Albers. 1995. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 274: 1771-1774.
32. von Eckardstein, A., H. Schulte, P. Cullen, and G. Assmann. 2001. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J. Am. Coll. Cardiol. 37: 434-439. (Pubitemid 32147250)
33. Erqou, S., S. Kaptoge, P. L. Perry, E. Di Angelantonio, A. Thompson, I. R. White, S. M. Marcovina, R. Collins, S. G. Thompson, and J. Danesh. 2009. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 302: 412-423.